This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Comparative Effects in Familial Type II Hyperlipoproteinemia

Charles J. Glueck, MD; Starr Ford, Jr., MD; Deborah Scheel; Paula Steiner

JAMA. 1972;222(6):676-681.

Abstract
Two bile acid-sequestrant anion exchange resins, colestipol (U-26, 597A) and cholestyramine resin (Questran), were given in doses of 20 gm/day for four months each in a 14-month placebo crossover study to 25 patients with familial type II hyperlipoproteinemia. Plasma cholesterol and β-lipoprotein cholesterol were reduced to normal levels in 20 and 22 subjects, respectively, by one or both drugs. Coupled with low cholesterol, low saturated fat, polyunsaturate-rich diet, colestipol and cholestyramine provide parallel and alternative approaches to normalization of cholesterol and β-lipoprotein cholesterol in familial type II hyperlipoproteinemia.

Author Affiliations
From the Lipoprotein Research Laboratory and the General Clinical Research Center, University of Cincinnati College of Medicine, and Cincinnati General Hospital.

Footnotes
Reprint requests to 234 Goodman St, Cincinnati 45229 (Dr. Glueck).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mechanism of Hypocholesterolemic Action of S-8921 in Rats: S-8921 Inhibits Ileal Bile Acid Absorption
Ichihashi et al.
J. Pharmacol. Exp. Ther. 1998;284:43-50.
ABSTRACT | FULL TEXT  

Reducing High Blood Cholesterol Level With Drugs: Cost-effectiveness of Pharmacologic Management
Schulman et al.
JAMA 1990;264:3025-3033.
ABSTRACT